Lightspeed Management Company L.L.C. Takes $47.17 Million Position in Personalis, Inc. (NASDAQ:PSNL)

Lightspeed Management Company L.L.C. bought a new stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 8,160,734 shares of the company's stock, valued at approximately $47,169,000. Personalis comprises about 13.2% of Lightspeed Management Company L.L.C.'s holdings, making the stock its 4th largest position. Lightspeed Management Company L.L.C. owned about 11.55% of Personalis at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PSNL. JPMorgan Chase & Co. boosted its position in shares of Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after buying an additional 5,654 shares during the last quarter. Olympiad Research LP purchased a new position in shares of Personalis during the fourth quarter valued at approximately $59,000. Alpine Global Management LLC purchased a new position in shares of Personalis during the fourth quarter valued at approximately $60,000. SG Americas Securities LLC purchased a new position in shares of Personalis during the fourth quarter valued at approximately $63,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Personalis during the fourth quarter valued at approximately $64,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Stock Down 6.2%

PSNL stock traded down $0.32 during midday trading on Wednesday, hitting $4.82. The company's stock had a trading volume of 589,183 shares, compared to its average volume of 1,004,619. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20. The stock's 50-day moving average price is $3.71 and its 200 day moving average price is $4.47. The stock has a market cap of $425.73 million, a price-to-earnings ratio of -2.87 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $20.61 million for the quarter, compared to analysts' expectations of $17.41 million. As a group, equities analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

PSNL has been the topic of several research analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Craig Hallum initiated coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective on the stock. Finally, HC Wainwright boosted their price objective on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $8.00.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.